Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist at the Morrison Cancer Center, about the most exciting research presented at ASCO in 2019.
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the EORTC AMAROS trial of radiotherapy vs surgery of the axilla in breast cancer patients with a positive sentinel node.
Cancer Network spoke with Jennie Williams, PhD, and Jenny Paredes, a PhD student, about how tumor biology impacts chemotherapy response in African American vs Caucasian patients.
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Cancer Network spoke with Carlo Maley, PhD, about how strategies utilized in agriculture can be applied to drug resistance in oncology.
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.
Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.